Kornimate/medical-research-clean huggingface dataset:
thoracic paravertebral block for postoperative analgesia after video-assisted thoracic surgery.

Conditions: Pain, Postoperative

Summary: the use of paravertebral catheters is a recommended technique to achieve postoperative analgesia after thoracic surgery. to date there is no consensus on which drug regime (local anesthetics with or without opioid) is best. the aim of this prospective clinical trial is to determine wether the use of ropivacaine and sufentanil injected through a thoracic paravertebral catheter results in decreased acute postoperative pain compared with plain ropivacaine in patients after thoracoscopic lung surgery.


Eligibility criteria:
inclusion criteria: * patient scheduled for planned video-assisted thoracic surgery * patient that consent to participate * planned placement of paravertebral catheter * patient having a medical insurance exclusion criteria: * patient less than 18 years * refusal to participate * known pregnancy * known allergies to local anesthetics, sufentanil and /or to iodinated contrast material * intolerance to sufentanil and/or morphine * chronic consumption of opiates * preoperative chronic pain syndrome * patient having a contraindication to placement of paravertebrtal catheter

Keywords: paravertebral block regional anesthesia anesthetics local ropivacaine sufentanil pain postoperative chronic pain thoracic surgery video-assisted.
fractional co2 laser therapy for survivors of breast malignancies

Conditions: Breast Carcinoma; Cancer Survivor; Cervical Carcinoma; Dyspareunia; Vaginal Dryness

Summary: this pilot clinical trial studies how well fraction carbon dioxide (co2) laser therapy works in treating vaginal atrophy in patients with breast cancer. fraction co2 laser therapy uses intense beams of light to cut, burn, or destroy tissue and may remodel vaginal tissue and direct controlled thermal damage of vaginal mucosa.

primary objectives: i. to demonstrate the feasibility of fractionated co2 laser treatments in patients with breast cancer with vaginal atrophy by determining treatment completion rates and tolerability of treatment. ii. to demonstrate the efficacy of fractionated co2 laser treatments in patients with breast cancer with vaginal atrophy as determined by improvement from baseline to post treatment in the score of the vaginal assessment scale (vas). secondary objectives: i. sexual behavior/function as measured by the sexual experiences scare, global sexual satisfaction scale, female sexual function index (fsfi), and the female sexual distress scare (fsds). ii. other symptoms of urogenital atrophy using the urogenital distress inventory (udi). iii. overall patient assessment of symptoms by patient global impression of improvement scale (pgi-i). outline: patients undergo fractional co2 laser therapy every 4-6 weeks for 3 treatments. after completion of study treatment, patients are followed up at 4 weeks.

Eligibility criteria:
inclusion criteria: * women with non-metastatic breast cancer with any hormone receptor and her 2 neu status who have completed surgery, chemotherapy, and radiation and are currently on endocrine therapy, single agent herceptin, or observation * symptoms of urogenital atrophy including dyspareunia or vaginal dryness exclusion criteria: * patients with metastatic breast cancer * vaginal stenosis which would not allow vaginal probe to be placed (based on physician exam) * active genital infection at the time of enrollment (if present initially, can be treated and then patient can be re-evaluated for eligibility) * pelvic organ prolapse greater than stage ii * prior reconstructive pelvic surgery involving mesh * hormone replacement therapy, vaginal estrogen therapy, dhea, or biosynthetics within 6 weeks prior to enrollment
gastric acid rebound secretion measured by alkaline tide

Conditions: Condition Measuring Alkaline Tide and Filling Symptoms' Questionnaire After Abrupt or Gradual Step Down Cessation of PPI

Summary: gastro esophageal reflux disease and ulcer related or non-ulcer dyspepsia, attacks 20% of the western population. these millions of patients are treated continuously with ppi for different periods, many for many years. recently, rebound acid hypersecretion was recognized as a major clinical event after cessation of ppi therapy. sustained hypergastrinemia due to daily ppi therapy causes increased acid-secretory capacity that appears when the drug is stopped. the transient increase in blood and urinary ph following gastric secretion has been termed the alkaline tide phenomenon. carbonic acid, formed in the presence of the enzyme carbonic anhydrase, neutralizes intracellular hydroxyl ions produced as a result of luminal acid secretion. the bicarbonate generated is removed from the cell via the baso-lateral chloride bicarbonate exchanger. the investigators have shown in several studies that this phenomenon parallels acid secretion. thus, stimulation of acid secretion with test meal increased base excess maximally after 45 minutes and these changes parallel peak acid output measured in gastric aspirate. the investigators hypothesize that gradual step down cessation of ppi will prevent this clinical relevant event. by measuring alkaline tide after ppi cessation the investigators may prove this hypothesis.


Eligibility criteria:
inclusion criteria: * dyspepsia and reflux patients older than 18 exclusion criteria: * patients on ppi, patients with severe diseases, younger than 18 y, older than 80 y, un-cooperative, copd, uncompensated ihd, crf
evaluate the influence of electromagnetic field as an adjunctive non surgical treatment in implant with peri-implantitis

Conditions: Peri-Implantitis

Summary: the aim of the study is to compare between two non-surgical methods of treatment of peri-implantitis by using debridement and placing an healing abutment with electomagnetic field (med-magdent miniaturized device) in the test group and sham healing abutment in the control group ( sham med).

dental implants are common alternative for replacement at the time of tooth loss. the two common methods for treatment implant with inflammation include surgical and global non-surgical treatment. the non-surgical treatment includes soft tissue debridement with various tools which including manual, ultrasonic rotators, lasers and delayed release devices. using an electromagnetic field to induce bony healing in fractures and around implants is being investigated for studies and was found to be effective and safe. the electric field lowers osteoclasts activity, speeds up osteoid construction and stimulates creation blood vessels development. forty patients who will attend to the department of periodontology at rambam health care campus, at the school ofpostgraduate dentistry, which will meet the research criteria, will be recruited. all patients will exhibit a moderate-onset gum infection around one of the implants.

Eligibility criteria:
inclusion criteria: * written informed consent. * patients of 20 - 85 years. * pocket depth of 5-8 mm and bone loss of 3-5mm patients with fixed prosthodontics implant with standart width exclusion criteria: * heavy smokers (more than 10 cigarettes per day). * pregnant women * active periodontal disease * consumption of non steroidal anti inflammatory drugs
ndt on fall risk in cerebral palsied children

Conditions: Cerebral Palsy, Spastic; Falling

Summary: children with spastic cerebral palsy experience falls due to weakness in balance skills and abnormalities in gait parameters. it is necessary to improve the quality of life of these children by reducing the frequency of falling. aim of this study was to investigate the effect of neurodevelopmental treatment on the risk of falling and balance and to contribute to the literature on this subject. cases were randomized into study and control groups. at the beginning of the study, the balance skills of all the cases with spastic cerebral palsy were measured with the pediatric balance scale, and the gait parameters and fall risks were measured with the legsys temporospatial gait analysis device. then, an 8-week, case-specific, neurodevelopmental therapy program with intensive gait and balance training was applied to the study group in a 45-minute single session, 2 days a week. the control group received 8 weeks of conventional physiotherapy. at the end of the treatment process, the evaluations were repeated with the same methods.


Eligibility criteria:
inclusion criteria: * cerebral palsy diagnosis * spastic type * gross motor function classification system level i and ii exclusion criteria: * tendon release surgery or botox application in the last 6 months
effects of bobath approach with core stability to improve balance in stroke

Conditions: Balance; Distorted

Summary: bobath technique with core stability exercises to improve balance in stroke. randomized clinical trial study design will be followed. data will be collected from following centers: naseer hospital, north ravi hospital, bajwa hoaspital,minhaj physiotherapy centre, home visits. probability random sampling is used.


Eligibility criteria:
inclusion criteria: * age 30 - 65 * both gender * more than 1 month or less than 6 months since onset of stroke * gcs score 11 to 15 exclusion criteria: * consist of gcs less than 10 * any pathological fracture * diagnosed orthostatic hypotension * comorbidities like ihd and rheumatologic disease.
repetitive transcranial stimulation (rtms) in post stroke dysphagia

Conditions: Dysphagia; Stroke

Summary: the aim of this study is to assess if rtms on healthy hemisphere at one hertz could improve patients with post stroke dysphagia.


Eligibility criteria:
inclusion criteria: * dysphagia * first episode of stroke exclusion criteria: * swallowing disorder before stroke * previous episode of stroke * mms \< 20 no consent

Keywords: repetitive transcranial stimulation
optimizing hiv virologic outcomes for pregnant women in uganda

Conditions: HIV

Summary: the enhanced -sps study is a before and after cluster randomized trial that will be conducted in 14 public health facilities providing hiv care in southwestern uganda. the study will evaluate the effectiveness of a multi-component intervention package that targets barriers to achieving optimal viral suppression among pregnant and postpartum women infected with hiv. this will be in two phases; in phase 1 ("before"), all 14 clinics will have a baseline assessment of standard of care vl procedures and assess the barriers and facilitators to viral suppression for a period of 3 months. in phase 2 ("after"), 7 clinics randomized to control arm will continue to experience standard of care counseling procedures, and 7 clinics randomized to intervention will initiate the enhance-ps intervention. the phase 2 ("after") phase i will last at least 12 months.

the investigators will test the hypothesis that the enhanced viral load (vl) counseling and standardized peer mother support (enhanced-sps) intervention will increase viral load suppression among hiv-infected pregnant and post-partum women and increase retention of mothers in care hence resulting in reduced risk of vertical transmission in south western uganda. specific objectives are as follows: 1) to evaluate the effectiveness of an enhanced vl counseling and standardized peer mother support intervention on viral suppression among hiv infected pregnant women at 12 months of follow up; 2) to evaluate the effect of the enhanced counseling and peer support intervention on retention in care at 18 months postpartum follow up; the investigators will randomize 14 hiv clinics to the enhanced-sps multi-component intervention vs. standard of care procedures (intervention=7 clinics and control=7 clinics,n=70 mothers/health facility) ;3) to assess the facilitators and barriers of vl and enhanced vl counseling and peer mother support intervention at 9 \& 18 months of follow up.this will consider both patient and providers perspectives of the intervention implementation

Eligibility criteria:
inclusion criteria: 1. all pregnant women and breastfeeding mothers enrolled in the mother baby care points/hiv clinics with documented hiv infection 2. . hiv infected pregnant women reporting for their first anc within the study clinics or newly identified hiv positive mothers from the anc clinics/breastfeeding exclusion criteria: 3. . all women who will be critically ill and unable to communicate 4. . those not willing to consent to participate in the study 5. . women who will not be able to understand all information concerning the study

Keywords: pregnant woman
intra-arterial microplasmin administration in patients with acute peripheral arterial occlusion

Conditions: Arterial Occlusive Diseases

Summary: the purpose of the trial is to evaluate the safety and efficacy of microplasmin administration in patients with acute peripheral arterial occlusion.

this clinical trial is designed as an open-label, dose-escalating, single-centre trial of weight-adjusted dose regimens of microplasmin administered intra-arterially as an infusion to patients with acute peripheral arterial occlusion. patients who meet all inclusion criteria and none of the exclusion criteria will be administered study drug for up to 4 hours. different dose regimens will be evaluated in an ascending-dose fashion; an infusion will be administered for up to 4 hours.

Eligibility criteria:
inclusion criteria: * patients presenting within 14 days of onset of acute thrombotic or embolic arterial occlusion of a lower extremity (native vessel or bypass graft). * complete occlusion of infrarenal vessel or bypass graft, as determined by angiography. * lower extremity ischemia graded as svs/iscs (society of vascular surgery/ international society for cardiovascular surgery) class i or ii (a or b). * negative urine pregnancy test (pregnancy test only required for females of child-bearing potential not using an accepted method of contraception). exclusion criteria: * profound ischemia with permanent motor paresis or sensory loss (or ischemic process deemed irreversible, i.e. class iii). * occlusion not penetrable by the infusion guide wire. * known or suspected allergy to contrast agents or heparin sodium. * active bleeding or known hemorrhagic diathesis. * stroke in the previous 6 months or transient ischemic attack in the previous 2 months.

Keywords: arterial occlusion thromboembolism acute peripheral arterial occlusion
enzastaurin as second and third-line treatment for non-small cell lung cancer.

Conditions: Non-Small-Cell Lung Carcinoma

Summary: enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.


Eligibility criteria:
inclusion criteria: * must be at least 18 years old * must have been diagnosed with advanced or metastatic non-small cell lung cancer * must be able to visit the doctor's office every 28 days for 6 months or longer. exclusion criteria: * pregnant or breastfeeding women * have other significant medical problems as determined by your physician * are unable to swallow tablets * have a history of significant heart disease
immersive versus passive virtual reality on upper limb pain and range of motion in pediatric burn

Conditions: Virtual Reality; Immersive Virtual Reality; Pediatric Burn; Passive Virtual Reality

Summary: the purpose of the present study was to declare the difference between using immersive virtual reality vs passive virtual reality on pain management and improvement of rom post physiotherapy exercise and mobilization sessions in pediatric burn patients.

burn injuries are devastating and cause long-term damage to health. thermal injuries, caused by hot liquids, solids, or fire, account for the majority of these injuries. around 11 million burn cases occur annually worldwide. rehabilitation aims to improve joint range od motion and control pain. nonpharmocologic strategies like hypnosis and vr systems have shown promise in pain control. multidisciplinary interventions from psychologists, physiotherapists, and pain management specialists can contribute to patient recovery. vr offers a holistic care device for pediatric burn patients.

Eligibility criteria:
inclusion criteria: 1. sixty patients have 2nd degree thermal burn injury, from both genders their ages will be ranged from 7 - 17 years old. 2. they will be diagnosed by their physicians with 2nd degree thermal burn injury affecting upper limbs and referred for physical therapy management . 3. tbsa calculated up to 9 for one upper limb. 4. the patients will be in the acute stage post burn injury; the duration of burn will be 3 weeks post injury. 5. medically and psychologically stable patients exclusion criteria: the potential participants will be excluded if they meet one of the following criteria: 1. cardiac diseases. 2. hand burn 3. exposed tendons. 4. patients who suffer from skin diseases, diabetes, varicose veins, and peripheral vascular diseases. 5. patients with life threatening disorders as renal failure, myocardial infarction or other similar diseases. 6. patients with facial burn. 7. patients will have an inability to tolerate visual stimulation (e.g., susceptibility to migraines aggravated by light) or inability to tolerate the head mounted display (e.g., sensitivity to touch around the face and head). 8. patients with visual or auditory disorders. 9. patients with unstable fractures. 10. central nervous system (cns) problems. 11. patients with medical red flags as severe psychiatric disorder or cognitive deficits . 12. medically unstable and uncooperative patients.
sb-742457 and donepezil in alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to find out if sb-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate alzheimer's disease. sb-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with alzheimer's disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of probable mild-to-moderate alzheimer's disease as determined by the nincds-adrda and dsm-iv criteria with an mmse score of 12-24. * subjects and their caregivers must provide informed consent prior to study entry. * adequate blood pressure and laboratory values. exclusion criteria: * females of child-bearing potential. * have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin b12 deficiency or thyroid deficiency. * subjects taking medication for alzheimers disease or centrally acting agents which might impact study outcomes. * subjects taking agents for which there is a theoretical risk of interaction with sb-742457 or donepezil. * subjects with conditions which might be exacerbated by exposure to donepezil. * subjects with known hypersensitivity to sunlight or seizures.

Keywords: alzheimer's disease cognition global functioning symptomatic sb-742457
adherence to otezla

Conditions: Psoriasis

Summary: most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. while limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.

psoriasis patients prefer oral treatments and are more adherent to orals than to topicals, but adherence to oral treatment of psoriasis may still be limited, compromising treatment outcomes. how well the medication works in the patients who take treatment regularly is not well characterized.

Eligibility criteria:
inclusion criteria: * adult 18 years or older * diagnosis of mild psoriasis with otezla recommendation * non-pregnant * english speaking exclusion criteria: * under 18 years of age * not diagnosis of mild psoriasis * pregnant * non-english speaking
clinical evaluation of two new silicone hydrogel multifocal products

Conditions: Presbyopia

Summary: the objective of this trial is compare the visual performance, ratings, and preference of two multifocal, soft contact lenses.


Eligibility criteria:
inclusion criteria: * be at least 35 years of age * best-corrected distance visual acuity of at least 20/40 in each eye. * spectacle add between +0.75d and +1.50d (inclusive). * able to be fit in available study sphere powers (-1.00 to -5.00d) * currently wearing soft contact lenses at least 5 days a week. * other protocol inclusion/exclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks immediately prior to enrollment. * currently enrolled in an ophthalmic clinical trial. * evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions. * any use of medications for which contact lens wear could be contraindicated as determined by the investigator. * astigmatism ≥ 1.00d. * currently wearing either of the study products. * other protocol inclusion/exclusion criteria may apply.
effects of mediterranean diet based intervention in breast cancer patients

Conditions: Breast Cancer; Obesity

Summary: the purpose of this randomized clinical trial is to examine the effects of mediterranean diet based intervention on inflammation and metabolic risk factors in overweight or obese postmenopausal women with breast cancer receiving adjuvant hormone therapy.


Eligibility criteria:
inclusion criteria: * breast cancer patients who are receiving adjuvant hormone therapy after diagnosed with breast cancer stage ⅰ-ⅲ and have completed cancer treatment including breast surgery and/or adjuvant chemotherapy, radiotherapy * postmenopausal women * body mass index (bmi) ≥23 kg/m2 * able to speak and read korean * able to comply with all required study procedures and schedule * willing and able to give written informed consent exclusion criteria: * participants with cancer recurrence or metastasis * participants with weight change more than 5kg in the previous 3 months * participants with secondary causes of obesity, such as hypothyroidism * participants with hepatic disease (aspartate aminotransferase (ast)/alanine aminotransferase (alt) \>3 x institutional upper limit of normal) or renal disease (serum creatinine \>2.0 mg/dl) * participants with serious psychiatric illness, including bipolar disorder, schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation * participants who are taking weight loss medications * participants who are receiving systemic corticosteroid therapy * participants with alcohol abuse or dependence * any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study